{"url_path":"/sec/glsi/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1799788/0001493152-26-027150-index.html","accession_number":"0001493152-26-027150","cik":"0001799788","ticker":"GLSI","issuer_name":"Greenwich LifeSciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1799788/0001493152-26-027150-index.html","primary_entity_key":"0001799788","primary_entity_name":"Greenwich LifeSciences, Inc."},"word_count":591,"has_tables":true,"body_markdown":"false\n--12-31\nQ1\n0001799788\n\n0001799788\n\n2026-01-01\n2026-03-31\n\n0001799788\n\n2026-05-26\n\n0001799788\n\n2026-03-31\n\n0001799788\n\n2025-12-31\n\n0001799788\n\n2025-01-01\n2025-03-31\n\n0001799788\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001799788\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001799788\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001799788\n\n2024-12-31\n\n0001799788\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001799788\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001799788\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001799788\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001799788\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001799788\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001799788\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001799788\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001799788\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001799788\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001799788\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001799788\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001799788\n\n2025-03-31\n\n0001799788\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001799788\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001799788\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001799788\n\nus-gaap:ConvertiblePreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001799788\n\nus-gaap:ConvertiblePreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001799788\n\nGLSI:TwoFamilyMembersMember\n\n2026-01-01\n2026-03-31\n\n0001799788\n\nGLSI:TwoFamilyMembersMember\n\n2025-01-01\n2025-03-31\n\n0001799788\n\nGLSI:LicenseAgreementMember\nGLSI:TheHenryMJacksonFoundationMember\n\n2009-04-01\n2009-04-30\n\n0001799788\n\nGLSI:LicenseAgreementMember\nGLSI:TheHenryMJacksonFoundationMember\n\n2009-04-30\n\n0001799788\n\nGLSI:LicenseAgreementMember\nGLSI:TheHenryMJacksonFoundationMember\n\n2009-04-01\n2009-04-30\n\n0001799788\n\n2025-01-01\n2025-12-31\n\n0001799788\n\n2024-01-01\n2024-12-31\n\n0001799788\n\nGLSI:ATMAgreementMember\n\n2026-01-01\n2026-03-31\n\n0001799788\n\nGLSI:ATMAgreementMember\n\n2026-03-31\n\n0001799788\n\nGLSI:ATMAgreementMember\n\n2025-01-01\n2025-03-31\n\n0001799788\n\nGLSI:ATMAgreementMember\n\n2025-03-31\n\n0001799788\n\nus-gaap:SubsequentEventMember\nus-gaap:CommonStockMember\n\n2026-05-26\n2026-05-26\n\n0001799788\n\nGLSI:TwoThousandNineteenEquityIncentivePlanMember\n\n2022-06-22\n2022-06-22\n\n0001799788\n\nGLSI:TwoThousandNineteenEquityIncentivePlanMember\n\n2026-01-01\n2026-03-31\n\n0001799788\n\nGLSI:TwoThousandNineteenEquityIncentivePlanMember\n\n2025-01-01\n2025-03-31\n\n0001799788\n\nGLSI:TwoThousandTwentyFourEquityIncentivePlanMember\n\n2024-12-24\n2024-12-24\n\n0001799788\n\nGLSI:TwoThousandTwentyFourEquityIncentivePlanMember\n\n2026-01-01\n2026-03-31\n\n0001799788\n\nGLSI:TwoThousandTwentyFourEquityIncentivePlanMember\n\n2025-01-01\n2025-03-31\n\n0001799788\n\nGLSI:TwoThousandTwentyFourEquityIncentivePlanMember\n\n2025-11-13\n2025-11-13\n\n0001799788\n\nus-gaap:SubsequentEventMember\nGLSI:AtTheMarketOfferingMember\n\n2026-04-01\n2026-04-15\n\n0001799788\n\nus-gaap:SubsequentEventMember\nGLSI:AtTheMarketOfferingMember\n\n2026-04-15\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**Form\n10-Q**\n\n \n\n**(Mark\nOne)**\n\n \n\n☒\n**QUARTERLY\nREPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe quarterly period ended March 31, 2026**\n\n \n\n**☐**\n**TRANSITION\nREPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n** **\n\n**For\nthe transition period from to**\n\n \n\n**COMMISSION\nFILE NUMBER 001-39555**\n\n \n\n**GREENWICH\nLIFESCIENCES, INC.**\n\n(Exact\nName of registrant as specified in its charter)\n\n \n\n**Delaware**\n \n**20-5473709**\n\n(State\nor other jurisdiction\n\nof\nincorporation or organization)\n\n \n\n(I.R.S.\nEmployer\n\nIdentification\nNo.)\n\n \n\n**3992 Bluebonnet\nDr., Building 14, Stafford, Texas**\n \n**77477**\n\n(Address\nof principal executive offices)\n \n(Zip\nCode)\n\n \n\n**(832)\n819-3232**\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\n**Title\nof each class:**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which registered:**\n\nCommon Stock\n \nGLSI\n \nNasdaq Capital Market\n\n \n\nIndicate\nby check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding\n12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing\nrequirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data\nFile required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding\n12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,\nor an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller\nreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge\naccelerated filer ☐\n \nAccelerated\nfiler ☐\n \nNon-accelerated\nfiler ☒\n \nSmaller\nreporting company ☒\n \nEmerging\ngrowth company ☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAs\nof May 26, 2026, the issuer had 14,678,208 shares of Common Stock issued and outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**GREENWICH\nLIFESCIENCES, INC.**\n\n \n\n**Table\nof Contents**\n\n \n\n \n \n**Page**\n\n**PART I**\n**FINANCIAL INFORMATION**\n3"}